Janet Woodcock

American physician and public health administrator

File:Janet Woodcock (2021).png

Janet Woodcock in 2021

Janet Woodcock is an American physician and public health administrator who has played a significant role in the FDA. She is known for her work in drug regulation and public health policy.

Early Life and Education

Janet Woodcock was born in Washington, Pennsylvania. She attended Bucknell University, where she earned a Bachelor of Science degree in chemistry. She then went on to receive her medical degree from the Northwestern University Feinberg School of Medicine.

Career

Early Career

After completing her medical training, Woodcock worked in various medical and research positions. She was involved in clinical research and patient care, which laid the foundation for her future work in drug regulation.

FDA Career

Woodcock joined the FDA in 1986. She has held several key positions within the agency, including Director of the Center for Drug Evaluation and Research (CDER). In this role, she was responsible for overseeing the evaluation and approval of new drugs, ensuring their safety and efficacy for public use.

Acting Commissioner

In 2021, Woodcock served as the Acting Commissioner of the FDA. During her tenure, she focused on addressing the challenges posed by the COVID-19 pandemic, including the approval and distribution of COVID-19 vaccines.

Contributions to Drug Regulation

Woodcock has been a strong advocate for modernizing the drug approval process. She has worked to implement new technologies and methodologies to improve the efficiency and effectiveness of drug evaluations. Her efforts have been instrumental in advancing the FDA's mission to protect public health.

Awards and Recognition

Throughout her career, Woodcock has received numerous awards for her contributions to public health and drug regulation. Her leadership and dedication have been recognized by various professional organizations and government bodies.

Related pages

• United States Food and Drug Administration
• COVID-19 pandemic
• Drug regulation